Agios Pharmaceuticals (AGIO) Other Non-Current Assets (2012 - 2026)

Agios Pharmaceuticals has reported Other Non-Current Assets for 15 years, with the latest figure at $3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 16.73% year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (down 16.73% YoY), and the FY2025 full-year result was $3.9 million, down 16.79% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $3.9 million, roughly flat from $3.9 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $4.7 million in Q4 2024, with the low at $2.9 million in Q1 2022.
• Historically, Other Non-Current Assets has averaged $4.0 million across 5 years, with a median of $4.0 million in 2022.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 36.41% — and 2025, when it fell 16.79%.
• Agios Pharmaceuticals' Other Non-Current Assets stood at $4.0 million in 2022, then advanced by 2.55% to $4.1 million in 2023, then gained by 16.44% to $4.7 million in 2024, then slipped by 16.79% to $3.9 million in 2025, then changed by 0.0% to $3.9 million in 2026.
• The last three Other Non-Current Assets figures came in at $3.9 million (Q1 2026), $3.9 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.